A large U.S. cohort study presented at the American Heart Association Scientific Sessions found that middle-aged adults with low HDL cholesterol levels ( 50 mg/dL) faced a 33% higher risk of developing...
A recent randomized clinical trial demonstrated that a nurse and social worker-led palliative telecare intervention improved quality of life, mental health, and disease-specific outcomes for patients with...
A nationwide analysis of over 1.4 million hospitalizations of patients with diabetic ketoacidosis revealed gender-based differences in cardiovascular outcomes. Men had higher rates of mortality and...
Preoperative diastolic dysfunction significantly elevates the risk of major adverse cardiac events and long-term mortality in patients undergoing hip fracture surgery, according to a retrospective cohort...
Despite advancements in guideline-directed therapy, heart failure readmissions remain high. At the American College of Physicians Internal Medicine Meeting 2025, Shudhanshu Alishetti, MD, outlined how...
In a large, matched-cohort study, patients with coronary artery disease receiving colchicine plus an SGLT2 inhibitor had significantly lower risks of mortality, MACE, ischemic stroke, and atrial...
A retrospective cohort study suggested that colchicine prophylaxis at urate-lowering therapy initiation may lower cardiovascular event risk in patients with gout.
A study assesses whether the dual sodium–glucose co-transporter (SGLT) 1/2 inhibitor sotagliflozin reduces ischemic events in diabetes and kidney disease.
The FDA has proposed new draft guidance to improve the accuracy of pulse oximeters across all skin tones, addressing long-standing concerns about potential disparities in performance.
Acoramidis, an oral therapy, is now approved to reduce cardiovascular-related deaths and hospitalizations in adults with hereditary or wild-type ATTR-CM.
